| Literature DB >> 27999534 |
Andrea Canessa1, Nicolò G Pozzi1, Gabriele Arnulfo1, Joachim Brumberg2, Martin M Reich1, Gianni Pezzoli3, Maria F Ghilardi4, Cordula Matthies5, Frank Steigerwald1, Jens Volkmann1, Ioannis U Isaias1.
Abstract
Activation of the basal ganglia has been shown during the preparation and execution of movement. However, the functional interaction of cortical and subcortical brain areas during movement and the relative contribution of dopaminergic striatal innervation remains unclear. We recorded local field potential (LFP) activity from the subthalamic nucleus (STN) and high-density electroencephalography (EEG) signals in four patients with Parkinson's disease (PD) off dopaminergic medication during a multi-joint motor task performed with their dominant and non-dominant hand. Recordings were performed by means of a fully-implantable deep brain stimulation (DBS) device at 4 months after surgery. Three patients also performed a single-photon computed tomography (SPECT) with [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (FP-CIT) to assess striatal dopaminergic innervation. Unilateral movement execution led to event-related desynchronization (ERD) followed by a rebound after movement termination event-related synchronization (ERS) of oscillatory beta activity in the STN and primary sensorimotor cortex of both hemispheres. Dopamine deficiency directly influenced movement-related beta-modulation, with greater beta-suppression in the most dopamine-depleted hemisphere for both ipsi- and contralateral hand movements. Cortical-subcortical, but not interhemispheric subcortical coherencies were modulated by movement and influenced by striatal dopaminergic innervation, being stronger in the most dopamine-depleted hemisphere. The data are consistent with a role of dopamine in shielding subcortical structures from an excessive cortical entrapment and cross-hemispheric coupling, thus allowing fine-tuning of movement.Entities:
Keywords: Parkinson’s disease; beta oscillations; coherence analysis; imaging; motor control; movement disorders; subthalamic nucleus
Year: 2016 PMID: 27999534 PMCID: PMC5138226 DOI: 10.3389/fnhum.2016.00611
Source DB: PubMed Journal: Front Hum Neurosci ISSN: 1662-5161 Impact factor: 3.169
Sample characteristics.
| Subject | Gender | Age at surgery (year) | Disease duration at surgery (year) | LEDD pre-DBS (mg) | UPDRS pre-DBS meds-off (score) | UPDRS pre-DBS meds-on (score) | LEDD post-DBS (mg) | UPDRS post-DBS meds-off, stim-on (score) |
|---|---|---|---|---|---|---|---|---|
| wue2* | male | 65 | 10 | 1100 | 40 | 23 | 800 | 19 |
| wue3 | male | 61 | 18 | 2725 | 40 | 9 | 600 | 13 |
| wue5* | male | 67 | 17 | 1050 | 49 | 24 | 500 | 13 |
| wue6 | male | 51 | 11 | 1133 | 47 | 12 | 180 | 9 |
| wue7 | male | 61 | 10 | 650 | 43 | 24 | 220 | 19 |
| wue9* | male | 55 | 19 | 1200 | 50 | 11 | 730 | 16 |
| wue11* | female | 53 | 11 | 1300 | 55 | 4 | 460 | 9 |
Demographic and clinical information. Before surgery participants were tested after overnight withdrawal of all dopaminergic medications (meds-off). To evaluate the effect of levodopa (meds-on), the patient had turned into a good quality “on-state” upon receiving 1–1.5-times the levodopa-equivalent of the preoperative morning dose. After surgery, all patients were evaluated in meds-off condition but under chronically effective STN stimulation (meds-off, stim-on). *Indicates the four patients (i.e., wue2, 5, 9 and 11) who were able to complete the motor task (i.e., with both hands in the required amount of time, please refer to .
Molecular imaging data.
| Subject | Percentage loss of DAT binding | STN− | AI Striatum | |||||
|---|---|---|---|---|---|---|---|---|
| Putamen right | Putamen left | Caudate n. right | Caudate n. left | Striatum right | Striatum left | |||
| wue2* | 57.87 | 73.61 | 43.48 | 65.22 | 47.53 | 67.71 | L | 47.62 |
| wue3 | 87.04 | 85.65 | 87.75 | 80.63 | 86.55 | 82.06 | R | 28.57 |
| wue5* | - | - | - | - | - | - | R§ | - |
| wue6 | 57.87 | 72.69 | 38.34 | 48.22 | 46.19 | 57.40 | L | 23.26 |
| wue7 | 63.43 | 70.37 | 51.78 | 63.64 | 55.16 | 65.92 | L | 27.27 |
| wue9* | 82.87 | 77.78 | 75.49 | 71.54 | 78.03 | 72.65 | R | 21.82 |
| wue11* | 65.74 | 63.43 | 44.27 | 54.55 | 52.91 | 56.95 | L | 8.96 |
Percentage loss of DAT binding values calculated with respect to a group of 15 healthy subjects (see Table S1). The DAT binding values of the striatum were used to identify the relative STN− and MC− or STN+ and MC+. We used the whole striatum, rather than its motor part (i.e., the putamen), as the boundaries between the putamen and the caudate nucleus are uncertain in SPECT images. One subject (i.e., wue5) was not willing to perform a SPECT, and STN− or MC− and STN+ or MC+ were based on UPDRS-III score as indicated by §. The clinically most affected hand (higher UPDRS scores) always corresponded to the striatum with less nigro-striatal dopaminergic innervation. The AI was calculated as the relative change of BP.
Clinical data.
| wue2 | wue5 | wue9 | wue11 | ||
|---|---|---|---|---|---|
| UPDRS-III meds-off | Total hemibody-score right | 20 | 13 | 12 | 22 |
| Total hemibody-score left | 10 | 19 | 22 | 13 | |
| Tremor subscore right | 4 | 0 | 0 | 0 | |
| Tremor subscore left | 0 | 1 | 1 | 0 | |
| Rigidity-bradykinesia subscore right | 16 | 13 | 12 | 22 | |
| Rigidity-bradykinesia subscore left | 10 | 18 | 21 | 13 | |
| UPDRS-III meds-on | Total hemibody-score right | 13 | 10 | 0 | 1 |
| Total hemibody-score left | 4 | 9 | 7 | 0 | |
| Tremor subscore right | 3 | 0 | 0 | 0 | |
| Tremor subscore left | 0 | 0 | 0 | 0 | |
| Rigidity-bradykinesia subscore right | 10 | 10 | 0 | 1 | |
| Rigidity-bradykinesia subscore left | 4 | 9 | 7 | 0 |
UPDRS-III subscores of the four subjects who completed the study protocol. We found a strong lateralization of clinical symptoms. In meds-off condition, the median UPDRS-III score of the most and least affected hemibodies were 22 (range 19–22) and 12 (range 10–13) respectively. UPDRS-III, Unified Parkinson Disease Rating Scale motor part.
Behavioral data.
| Least-affected | Most-affected | Dominant (right) | Non-dominant (left) | |
|---|---|---|---|---|
| OT (ms) | 460 (304–693)* | 412 (281–600)* | 437 (300–675) | 435 (289–626) |
| MT (ms) | 725 (378–1092) | 766 (425–1273) | 699 (383–1074)• | 792 (413–1278)• |
| PV (cm/s) | 8.13 (4.25–15.11) | 7.79 (3.76–14.93) | 8.34 (4.47–15.01) | 7.58 (3.74–15.06) |
| PA (cm/s2) | 104.09 (32.94–265.65) | 103.59 (30.98–275.01) | 110.03 (32.52–287.88)§ | 97.65 (31.69–251.81)§ |
| PL (cm) | 4.82 (3.79–5.92)⋄ | 5.08 (3.91–6.75)⋄ | 5.17 (4.12–6.75)# | 4.73 (3.72–5.77)# |
| RT (s) | 2.04 (1.41–2.78) | 2.08 (1.48–2.89) | 2.03 (1.4–2.77) | 2.05 (1.47–2.87) |
In all patients, the most-affected side was contralateral to the striatum with less DAT binding values. All subjects were right-handed, as assessed by a modified Edinburgh handedness inventory. DAT, dopamine reuptake transporter, OT, onset time (time from target appearance to movement onset); MT, movement time (time from movement onset to reversal); PV, peak velocity; PA, peak acceleration; PL, path length (from onset to reversal); RT, return time (the time needed to come back to the central target). Values are expressed as median and range. Statistical significance was assessed by means of a two sample unpaired .
Figure 1Movement-related beta-modulation with respect to the more and less dopamine-depleted hemisphere. The blue lines represent the movement performed with the hand contralateral to the examined brain structure, red lines with the ipsilateral one. Solid lines represent the average across subjects and thin lines the beta-modulation of each subject. The super-imposed vertical dotted line at 0 s shows the return time (RT). We also indicated with a dotted line at −1.7 s the mean onset time (OT) of all trials (see also Figure S1), as a rough indication of movement OT. (B) Movement-related beta-modulation for each subject across all valid trials and the corresponding [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (FP-CIT) and single-photon computed tomography (SPECT) images. (C) Movement-related power change in left and right (MCL and MCR) and subthalamic nucleus (STNL and STNR). The yellow lines represent the movement performed with the dominant hand, the green lines with the non-dominant one. Solid lines represent the average across subjects and thin lines the beta-modulation of each subject. Values are reported in Table 4.
Beta-oscillation power analyses.
| β-power raw data | wue2 | wue5 | wue9 | wue11 | ||||
|---|---|---|---|---|---|---|---|---|
| IPSI | CONTRA | IPSI | CONTRA | IPSI | CONTRA | IPSI | CONTRA | |
| STN− (mV2) | 4.48e-02 | 4.98e-02 | 3.27e-02 | 3.46e-02 | 18.8e-02 | 18.2e-02 | 9.08e-02 | 8.57e-02 |
| STN+ (mV2) | 1.19e-02 | 1.17e-02 | 3.38e-02 | 3.40e-02 | 1.82e-02 | 1.69e-02 | 2.73e-02 | 2.50e-02 |
| STN− (-dB) | 73.48 | 73.02 | 74.85 | 74.61 | 67.26 | 67.40 | 70.41 | 70.67 |
| STN+ (-dB) | 79.24 | 79.33 | 74.71 | 74.68 | 77.40 | 77.71 | 75.63 | 76.01 |
Spectral power of the neuronal oscillations in the beta frequency range (13–35 Hz) was computed in each subject who completed the study protocol for both the STN and task (i.e., movement with the right and left hand). “IPSI” and “CONTRA” refer to movement performed with the hand ipsilateral or contralateral to the examined STN (STN− or STN+). “−” (MC− and STN−) and “+” (MC+ and STN+) refer instead to the side with less and more striatal dopaminergic innervation or the more and less clinically affected hemibody (for wue05). MC, motor cortex; STN, subthalamic nucleus.
.
| A | STN−CONTRA | STN+CONTRA | STN−IPSI | STN+IPSI | STN−CONTRA | STN+IPSI | STN−IPSI | STN+CONTRA | STN−IPSI | STN−CONTRA | STN+IPSI | STN+CONTRA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| wue02 | 49.94 | 17.62* | 43.95 | 17.33* | 49.94 | 17.33* | 43.95 | 17.62* | 43.95 | 49.94 | 17.33 | 17.62 |
| wue05 | 51.74 | 16.90* | 25.40 | 19.19 | 51.74 | 19.19* | 25.40 | 16.90 | 25.40 | 51.74* | 19.19 | 16.90 |
| wue09 | 64.74 | 36.20* | 48.51 | 29.74* | 64.74 | 29.74* | 48.51 | 36.20* | 48.51 | 36.20* | 29.74 | 36.20 |
| wue11 | 63.93 | 31.75* | 37.01 | 38.57 | 63.93 | 38.57* | 37.01 | 31.75 | 37.01 | 63.93* | 38.57 | 31.75 |
| wue02 | 32.45 | 26.84 | 19.67 | 22.64 | 32.45 | 22.64 | 19.67 | 26.84 | 19.67 | 32.45* | 22.64 | 26.84 |
| wue05 | 55.88 | 57.13 | 42.54 | 63.77* | 55.88 | 63.77 | 42.54 | 57.13 | 42.54 | 55.88 | 63.77 | 57.13 |
| wue09 | 56.76 | 59.31 | 31.75 | 57.39* | 56.76 | 57.39 | 31.75 | 59.31* | 31.75 | 56.76* | 57.39 | 59.31 |
| wue11 | 60.57 | 34.75* | 36.03 | 63.80* | 60.57 | 63.80 | 36.03 | 34.75 | 36.03 | 60.57* | 63.80 | 34.75* |
Significant differences considering separately the STN (A) and the MC (B) for all the six possible comparisons. Brain structures are distinguished with regards to striatal dopaminergic innervation loss and clinical severity. In each cell, we show the average rebound value, expressed as percentage of relative power change (see also Figure .
Figure 2Coherence analyses. Subcortical- (i.e., CohSTN−/STN+) and cortical-subcortical coherence (i.e., CohSTN−/MC−, CohSTN−/MC+ and CohSTN+/MC−, CohSTN+/MC+) are reported for each subject with respect to STN− and STN+. White color shows lack of coherence. From blue to red color we show increasing significant coherence between brain structures. Results were mirrored by iCoh, thus supporting the lack of volume conduction artifact (Supplementary Material, Results, Figure S8). As in Figure 1, the super-imposed vertical dotted line at 0 s shows the RT. We also indicated, with a dotted line at −1.7 s, the mean OT of all trials (see also Figure S1) as a rough indication of movement OT. “IPSI” and “CONTRA” refer to movement performed with the hand ipsilateral or contralateral to the examined STN (STN− or STN+). “−” (MC− and STN−) and “+” (MC+ and STN+) refer instead to the side with less and more striatal dopaminergic innervation or the more and less clinically affected hemibody (for wue05). MC, motor cortex; STN, subthalamic nucleus. MC, motor cortex; STN, subthalamic nucleus.